Because MEK inhibitors should be effective against all KRAS variants, as well as somatic activating mutations in BRAF or MAP2K1 (which combined conservatively account for at least 50% of all sporadic bAVM cases), future consideration should be given to employing trametinib or other FDA-approved MEK inhibitors as a frontline, non-surgical therapy for treating bAVM. The gene discussed is MAP2K1; the disease is arteriovenous malformations of the brain.